Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-positive Breast Cancer”

962 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 962 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT06245824
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 51
Testing effectiveness (Phase 2)Looking for participantsNCT06176261
What this trial is testing

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Who this might be right for
Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more
Nancy Lin, MD 58
Large-scale testing (Phase 3)WithdrawnNCT03811418
What this trial is testing

Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CancerHER2-positive Breast Cancer
iOMEDICO AG
Testing effectiveness (Phase 2)Study completedNCT02536742
What this trial is testing

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 124
Early research (Phase 1)Study completedNCT01513083
What this trial is testing

Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Who this might be right for
Breast Cancer
Hoffmann-La Roche 28
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Testing effectiveness (Phase 2)Study completedNCT03213041
What this trial is testing

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Northwestern University 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06578286
What this trial is testing

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Who this might be right for
Breast Cancer
Fudan University 44
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Looking for participantsNCT04573231
What this trial is testing

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
University of Wisconsin, Madison 13
Testing effectiveness (Phase 2)Study completedNCT00371345
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 92
Testing effectiveness (Phase 2)UnknownNCT03204734
What this trial is testing

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Very early researchNot Yet RecruitingNCT07671092
What this trial is testing

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Who this might be right for
Metastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast Cancer+2 more
RayzeBio, Inc. 40
Testing effectiveness (Phase 2)WithdrawnNCT01137994
What this trial is testing

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline
Early research (Phase 1)Study completedNCT00928330
What this trial is testing

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 57
Large-scale testing (Phase 3)Looking for participantsNCT05894239
What this trial is testing

Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 230
Next Page